Cancer-Associated Fibroblasts (CAFs): Key Players in the Tumor Microenvironment

Cancer is not driven solely by malignant cells—it thrives within a supportive environment known as the tumor microenvironment (TME). Among the most influential components of this environment are cancer-associated fibroblasts (CAFs), a specialized population of fibroblasts that undergo significant changes in response to cancer. Unlike normal fibroblasts, CAFs actively contribute to tumor progression by remodeling the extracellular matrix, promoting angiogenesis, suppressing immune responses, and fostering therapy resistance.

In this article, we will explore the origin, characteristics, and functions of CAFs, their impact on cancer progression and treatment, and the therapeutic strategies currently being developed to target them.

Origin and Characteristics of Cancer-Associated Fibroblasts (CAFs)

Cancer-associated fibroblasts (CAFs) represent a diverse and dynamic population of stromal cells within the tumor microenvironment (TME). Unlike normal fibroblasts that primarily maintain tissue structure, CAFs acquire tumor-promoting functions through cellular reprogramming triggered by cancer cells and their secreted factors.

Origin of CAFs

The exact origin of CAFs is heterogeneous, reflecting their plasticity:

• Resident fibroblasts: Local fibroblasts in tissue can be activated by growth factors such as TGF-β to adopt a CAF phenotype.
• Mesenchymal stem cells (MSCs): Bone marrow–derived MSCs can migrate into tumors and differentiate into CAF-like cells.
• Epithelial-to-mesenchymal transition (EMT): Cancer cells themselves may undergo EMT, giving rise to fibroblast-like cells that integrate into the stroma.
• Endothelial-to-mesenchymal transition (EndMT): Endothelial cells from tumor vasculature can also contribute to the CAF pool.

Molecular Markers of CAFs

Identifying CAFs is challenging due to their heterogeneity. They are commonly characterized by the expression of:

• α-SMA (alpha-smooth muscle actin): A hallmark marker indicating myofibroblast-like activity.
• Fibroblast activation protein (FAP): Highly expressed in CAFs and associated with tumor invasion.
• PDGFR-β (platelet-derived growth factor receptor beta): Linked to fibroblast proliferation and signaling.
• Vimentin & periostin: Cytoskeletal and extracellular proteins often elevated in activated fibroblasts.

Heterogeneity and Plasticity

CAFs are not a single uniform population. Studies have revealed subtypes with distinct roles—some driving tumor growth and invasion, others involved in immune modulation or extracellular matrix remodeling. This heterogeneity of CAFs complicates therapeutic strategies but also opens new avenues for precision medicine.

CAFs in the Tumor Microenvironment (TME)

The tumor microenvironment (TME) is a complex ecosystem where cancer cells coexist with stromal cells, immune cells, blood vessels, and extracellular matrix (ECM). Among these, cancer-associated fibroblasts (CAFs) are key architects of the tumor niche, actively shaping the environment to favor cancer progression.

Interaction with Cancer Cells

CAFs communicate with cancer cells through direct contact and the release of signaling molecules. This crosstalk supports tumor growth by:

• Stimulating proliferation via growth factors (e.g., HGF, EGF).
• Promoting epithelial-to-mesenchymal transition (EMT), enhancing invasive potential.
• Altering gene expression in tumor cells to support survival and migration.

Crosstalk with Immune and Endothelial Cells

CAFs extend their influence beyond tumor cells, interacting with other stromal and immune components:

• Immune modulation: CAFs secrete cytokines such as IL-6, CXCL12, and TGF-β, which suppress T-cell activity, promote regulatory T cells, and attract immunosuppressive macrophages.
• Angiogenesis: By producing VEGF and remodeling the ECM, CAFs stimulate endothelial cells to form new blood vessels, ensuring nutrient and oxygen supply for the tumor.

Extracellular Matrix Remodeling

CAFs are major contributors to ECM dynamics. They:

• Deposit ECM proteins like collagen and fibronectin.
• Release matrix metalloproteinases (MMPs), which degrade ECM and create migration pathways for cancer cells.
• Increase tissue stiffness, which enhances tumor cell invasion and metastasis.

CAF-Secreted Cytokines and Growth Factors

Through their secretome, CAFs create a pro-tumorigenic niche. Key molecules include:

• TGF-β: Induces fibroblast activation and immune suppression.
• IL-6: Promotes chronic inflammation and cancer cell survival.
• VEGF: Drives angiogenesis.
• CXCL12 (SDF-1): Attracts immune suppressor cells and supports tumor growth.

Functional Roles of CAFs in Cancer Progression

Cancer-associated fibroblasts (CAFs) are not passive bystanders—they are active drivers of cancer biology. By reshaping the tumor microenvironment (TME) and influencing multiple hallmarks of cancer, CAFs directly contribute to disease progression and poor patient outcomes.

CAFs and Tumor Growth

CAFs secrete a wide range of growth factors such as HGF (hepatocyte growth factor), EGF (epidermal growth factor), and FGF (fibroblast growth factor). These molecules stimulate tumor cell proliferation, sustain cancer metabolism, and protect malignant cells from apoptosis.

CAFs and Angiogenesis

To meet the high metabolic demands of growing tumors, CAFs promote the formation of new blood vessels by:

• Secreting VEGF and PDGF, which stimulate endothelial cell proliferation.
• Remodeling the extracellular matrix (ECM) to provide pathways for vessel sprouting.
• Supporting pericyte recruitment and vessel stabilization.

CAF-Mediated Immunosuppression

CAFs are central players in immune evasion mechanisms:

• Secreting TGF-β and IL-6, which impair cytotoxic T-cell activity.
• Producing CXCL12, which creates a physical barrier around tumor nests that excludes immune cells.
• Recruiting immunosuppressive cells such as regulatory T cells (Tregs) and M2 macrophages, further weakening anti-tumor immunity.

CAFs and Epithelial-to-Mesenchymal Transition (EMT)

Through paracrine signaling, CAFs induce EMT in cancer cells, a process where epithelial cells lose their polarity and gain invasive, migratory properties. This transition is a key step toward local invasion and metastasis.

CAFs in Metastasis and Invasion

CAFs facilitate metastatic spread by:

• Degrading ECM via matrix metalloproteinases (MMPs).
• Creating tracks within the stroma for cancer cells to migrate.
• Preparing distant pre-metastatic niches by secreting soluble factors that “condition” future metastatic sites.

Cancer-associated fibroblasts and Therapy Resistance

One of the most critical clinical implications of cancer-associated fibroblasts (CAFs) is their contribution to therapy resistance. By reshaping the tumor microenvironment and altering cancer cell behavior, CAFs reduce the effectiveness of chemotherapy, radiotherapy, targeted therapy, and immunotherapy.

Mechanisms of Drug Resistance Induced by CAFs

CAFs create a protective niche for tumor cells through several mechanisms:

• Drug sequestration and altered drug delivery: Dense extracellular matrix (ECM) produced by CAFs limits the penetration of therapeutic agents.
• Secretion of survival signals: Factors such as IL-6, TGF-β, and HGF activate pro-survival pathways (e.g., PI3K/AKT, NF-κB) in cancer cells.
• Induction of stem-like phenotypes: CAFs promote cancer stem cell (CSC) properties, which are inherently resistant to standard therapies.

Cancer-associated fibroblasts in Chemotherapy Resistance

CAFs release soluble factors that protect tumor cells from chemotherapy-induced apoptosis. For example:

• IL-6 and CXCL12 enhance cancer cell survival under chemotherapeutic stress.
• ECM stiffness reduces drug accessibility to tumor nests.

CAFs and Immunotherapy Failure

In the context of immunotherapy, CAFs act as immune barriers:

• They secrete CXCL12, which prevents T-cell infiltration into tumors.
• High CAF activity is associated with poor response to immune checkpoint inhibitors.
• CAF-induced immunosuppression hampers long-term benefits of immunotherapy.

CAFs and Radiotherapy Resistance

By promoting DNA damage repair and creating a hypoxic environment through abnormal vasculature, CAFs reduce tumor sensitivity to radiotherapy.

Targeting CAFs in Cancer Therapy

Given their central role in tumor progression and therapy resistance, cancer-associated fibroblasts (CAFs) have become promising targets in cancer treatment. However, the complexity and heterogeneity of CAFs make this a challenging field. Current research focuses on strategies to either eliminate CAFs, reprogram them into a less harmful state, or block their tumor-promoting signals.

Current Therapeutic Strategies

1. Fibroblast Activation Protein (FAP) Inhibitors
   • FAP is highly expressed on CAFs but minimally present in normal tissues, making it an attractive therapeutic target.
   • FAP-targeted drugs, antibodies, and CAR-T cell therapies are under investigation.
2. Stromal Depletion Approaches
   • Aiming to reduce CAF populations or disrupt their physical barrier functions in the tumor microenvironment.
   • Example: depletion of ECM components to improve drug delivery.
3. Blocking CAF-Derived Signaling Pathways
   • Inhibiting pathways such as TGF-β, IL-6/STAT3, or CXCL12/CXCR4 to counteract CAF-induced immunosuppression and drug resistance.

Emerging Approaches

1. CAF Reprogramming
   • Instead of eliminating CAFs, researchers aim to revert them to a quiescent, “normal fibroblast-like” state.
   • Drugs targeting epigenetic regulators and metabolic pathways are being tested for this purpose.
2. Nanotherapy and Drug Delivery Systems
   • Nanoparticles designed to specifically target CAFs or their secreted factors, improving delivery precision while reducing toxicity.
3. Combination Therapies
   • CAF-targeted therapies are being combined with immunotherapy, chemotherapy, and targeted therapy to overcome resistance and improve clinical outcomes.

Clinical Applications and Trials

Several early-phase clinical trials are currently investigating CAF-targeted therapies, with particular focus on pancreatic cancer, breast cancer, and lung cancer, where CAF activity is especially prominent.

Conclusion

Cancer-associated fibroblasts (CAFs) are central players in the tumor microenvironment, driving cancer growth, invasion, immune evasion, and therapy resistance. While their heterogeneity poses challenges, CAFs also represent promising diagnostic biomarkers and therapeutic targets. Ongoing research into CAF-targeted strategies, from FAP inhibitors to reprogramming approaches, may open new pathways toward more effective and personalized cancer treatments.

References

1. Biffi G, Tuveson DA. Diversity and Biology of Cancer-Associated Fibroblasts. Physiol Rev. 2021 Jan 1;101(1):147-176. doi: 10.1152/physrev.00048.2019.
2. Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022 Jul;3(7):793-807. doi: 10.1038/s43018-022-00411-z.
3. Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021 Dec;18(12):792-804. doi: 10.1038/s41571-021-00546-5.
4. Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity. Clin Cancer Res. 2023 Mar 14;29(6):1009-1016. doi: 10.1158/1078-0432.CCR-22-1031.
5. Hu D, Li Z, Zheng B, Lin X, Pan Y, Gong P, Zhuo W, Hu Y, Chen C, Chen L, Zhou J, Wang L. Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Commun (Lond). 2022 May;42(5):401-434. doi: 10.1002/cac2.12291.